Trimosulfa, a combination of trimethoprim and sulfamethoxazole, is a sequential dual folate synthesis inhibitor effective against a broad spectrum of bacteria. It is widely used in research for studying antimicrobial mechanisms and efficacy in both in vitro susceptibility assays and in vivo infection models.